Galapagos announces phase 2 study

[Fred]

The dose ranging study was posted in 2017.  Found the very detailed results....

I am having trouble finding where things are at with this research 

From Galapagos

Quote:

---

In February 2014, GSK stopped the lupus study due to a lack of effect and put the ulcerative colitis study on hold. In April 2014, GSK informed Galapagos that GSK2586184 met the primary endpoint in a Phase 2a study in psoriasis.

In August 2014, GSK informed Galapagos that they have assessed the overall risk:benefit profile of GSK2586184 and have elected to terminate all indications where GSK 2586184 is administered orally for chronic immuno-inflammatory disease (SLE, psoriasis, ulcerative colitis).

Development options for GSK2586184 in other potential indications are presently being explored by GSK.